Monopar Therapeutics Inc. announced a pricing of an underwritten registered offering involving 1.03 million shares of its common stock at $67.67 per share. The gross proceeds are expected to be approximately $100 million, with certain investors receiving pre-funded warrants. Monopar intends to use the net proceeds for general corporate purposes, including research and development and working capital. Additionally, the company plans to use up to $35 million to purchase shares of its common stock held by Tactic Pharma, LLC. The offering is expected to close on or about September 25, 2025, with Morgan Stanley, Leerink Partners, and Barclays as the lead book-running managers.

Read more at Nasdaq.: Monopar Announces Pricing Of $19.2 Mln Public Offering Of Common Stock